Pharmaceutical companies today are surrounded by data—clinical results, safety signals, real-world evidence—yet some of the most valuable opportunities remain hidden in plain sight. Statins are a striking example. For decades, observations of anti-inflammatory and immune-modulating effects were logged as secondary findings and largely set aside. Today, those same signals are driving serious research into statins’… View Article …
Pharmaceutical companies today are surrounded by data—clinical results, safety signals, real-world evidence—yet some of the most valuable opportunities remain hidden …
Pharma companies across the EU are facing a growing pressure that many still underestimate. The shift toward ePI requirements is not just another regulatory update, but a fundamental change in how product information must be created, managed and delivered. Under the new legislation, structured electronic product information is becoming a formal requirement, replacing static documents… View Article …
If you are looking for ISO 13485 risk management checklist for medical devices, you are likely not at the beginning—you are already facing pressure. On paper, ISO 13485 risk management seems straightforward: define risks, document them, and demonstrate control. But in practice, it quickly becomes one of the most difficult parts of your entire quality… View Article …
Companies operating in a GMP environment often believe their supply chain is under control – until something goes wrong. A single weak or insufficiently qualified GMP vendor can trigger audit findings, delays, or even product recalls. In regulated industries, vendors are considered an extension of your own operations, meaning their failures directly impact your compliance,… View Article …
The moment your device enters the market, the pressure doesn’t ease—it intensifies. Suddenly, you’re expected to prove, continuously, that your product remains safe and performs as intended in real-world use. That means collecting data, analyzing it, updating documentation, and feeding everything back into your quality and risk systems—again and again, for the entire lifecycle. This… View Article …
If you are searching for how to choose a drug safety consulting partner, it usually means one thing—you are already feeling the pressure of keeping your pharmacovigilance system under control. The problem is that drug safety is not static. It is a continuous process of detecting, assessing, and preventing adverse effects, where even small gaps… View Article …
Most companies don’t feel the problem with CMC at the beginning—it builds silently in the background, hidden behind progress, timelines, and the assumption that everything will “come together” before submission. But CMC doesn’t work that way. Because CMC assessment is not just a final check. It is the foundation that proves your product can be… View Article …
Companies searching for “rank the best training programs for pv teams” usually assume that choosing the right pharmacovigilance training will automatically solve compliance challenges. Investing in pv training feels like a logical, structured step—after all, teams need knowledge, and regulators expect trained personnel. But pharmacovigilance is not just about understanding guidelines; it is a system… View Article …
For every marketing authorization holder (MAH), pharmacovigilance is not just another operational function — it often becomes a constant source of pressure. MAHs are expected to monitor safety, manage risks, and remain inspection-ready at all times, while regulatory expectations continue to grow and evolve. The problem is that most marketing authorization holders quickly find themselves… View Article …
Many companies assume that hiring a RA consultant will immediately bring clarity and control to their regulatory process. On paper, it looks simple: bring in a regulatory affairs consultant, delegate the work, and move forward with confidence. But the reality often looks very different. Regulatory affairs consulting is a highly complex, evolving function that spans… View Article …
EUDAMED European Database on Medical Devices has for years been something companies could postpone. Even as MDR and IVDR reshaped regulatory expectations, many organisations treated it as a future requirement—important, but not urgent. That perception changed fundamentally in November 2025, when the notice confirming the functionality of the first four modules was officially published in… View Article …
Developing and maintaining pharmacovigilance today is no longer just an operational task — it is a constant balancing act between compliance, safety, and control. With increasing regulatory pressure, growing volumes of safety data, and the need for continuous inspection readiness, companies are under more strain than ever to ensure their pharmacovigilance systems actually work as… View Article …
Many companies enter the market with OTC products expecting a faster and simpler regulatory pathway—but quickly run into unexpected complexity. Even a single over-the-counter (OTC) product must meet strict requirements for safety, quality, and correct patient use without medical supervision, which regulators assess very carefully. The problem is that this complexity is often underestimated. Companies… View Article …
When developing class II medical devices, companies often underestimate what they are really stepping into. These devices are typically classified as medium to higher risk, which means stricter regulatory requirements, mandatory involvement of a Notified Body, and a more complex conformity assessment process than for lower-class devices . The problem is that this complexity doesn’t… View Article …
Developing combination products sounds like a strategic advantage—until the reality hits. These products combine drugs, medical devices, and/or biologics into one integrated solution, which immediately multiplies regulatory, technical, and operational complexity, as both pharmaceutical and device requirements must be met simultaneously. Companies quickly realize that what seemed like innovation turns into confusion. Teams struggle to… View Article …
Developing combination products sounds like a strategic advantage—until the reality hits. These products combine drugs, medical devices, and/or biologics into …
Biotech regulatory consulting becomes critical right after closing a Series A round, when most biotech companies expect acceleration — but instead, regulatory complexity starts slowing everything down. What initially looked like a clear path to clinic quickly turns into uncertainty around strategy, data requirements, and interactions with authorities. The problem is that regulatory affairs is… View Article …
Companies rarely search for signal detection service recommendations proactively — they do it when control over safety data starts slipping. What begins as a manageable pharmacovigilance activity quickly turns into a complex, high-pressure process, where growing data volumes, fragmented systems, and limited internal capacity make it difficult to identify what truly matters. The challenge is… View Article …
Bringing a product to market is only the beginning — what follows is often far more complex. If you are searching for post-marketing surveillance explained, you are likely trying to understand why this phase becomes so demanding in real life. Many companies underestimate how demanding post-market surveillance (PMS) can become once real-world data, safety signals,… View Article …
